Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 53M | 18M | 17M | 36M | 27M |
| Gross Profit | 15M | 8M | 8M | 10M | 10M |
| Operating Income | 2K | 161K | -821K | -7M | 3M |
| EBITDA | 8M | 2M | 1M | -2M | 4M |
| Net Income | 3K | -3M | -4M | -7M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.07
-10.83% today
1Y Change
-59.47%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regional Health Properties, Inc. (RHEP) is a Healthcare stock with listed on OTC. The stock last traded around $1.07 and down 59.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +189.9%, EPS growth of +163.0%, a dividend yield of 0.0%. What stands out right now is revenue +189.9%, EPS +163.0%, free cash flow -100.2% with operating margin -0.3% and ROIC -0.4%. Valuation is more restrained than many high-expectation growth names at P/E 0.0 and price/sales 0.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RHEP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RHEP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RHEP Max Drawdown
-68.53%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RHEP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$26.7M
-25.7% YoY
FY Net Income
-$1.2M
+82.8% YoY
Free Cash Flow
$4.8M
+223.1% YoY
Revenue Growth
+189.9%
EPS Growth
+163.0%
Gross Margin
27.5%
Net Margin
6.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 53M | 18M | 17M | 36M | 27M |
| Gross Profit | 15M | 8M | 8M | 10M | 10M |
| Operating Income | 2K | 161K | -821K | -7M | 3M |
| EBITDA | 8M | 2M | 1M | -2M | 4M |
| Net Income | 3K | -3M | -4M | -7M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3K | 582K | 953K | 843K | 7M |
| Total Assets | 69M | 60M | 62M | 69M | 106M |
| Total Liabilities | 64M | 63M | 62M | 65M | 95M |
| Shareholder Equity | 5M | -3M | 185K | 4M | 10M |
| Total Debt | 42M | 44M | 46M | 55M | 85M |
| Net Debt | 42M | 43M | 45M | 55M | 78M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
+236.1% YoY
Capital Expenditures
123K
+56.2% YoY
Free Cash Flow
5M
+223.1% YoY
Key ratios
Gross Margin
27.5%
Operating Margin
-0.3%
Net Margin
6.3%
ROE
-949.3%
Debt / Equity
8.43x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.